Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy

Yan Yang; Zheng Yang; Yun Yang

doi:10.3389/fimmu.2021.686031

Frontiers in Immunology (Jul 2021)

Potential Role of CD47-Directed Bispecific Antibodies in Cancer Immunotherapy

Yan Yang,
Zheng Yang,
Yun Yang

Affiliations

Yan Yang: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China
Zheng Yang: College of Public Health, School of Public Health, Zhengzhou University, Zhengzhou, China
Yun Yang: Department of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Xinxiang Medical University, Xinxiang, China

DOI: https://doi.org/10.3389/fimmu.2021.686031
Journal volume & issue: Vol. 12

Abstract

Read online

The prosperity of immunological therapy for cancer has aroused enormous passion for exploiting the novel targets of cancer immunotherapy. After the approval of blinatumomab, a bispecific antibody (bsAb) targeting on CD19 for acute lymphoblastic leukemia, a few of CD47-targeted bsAbs for cancer immunotherapy, are currently in clinical research. In our review of CD47-targeted bsAbs, we described the fundamental of bsAbs. Then, we summarized the information of four undergoing phase I researches, reviewed the main toxicities relevant to CD47-targeted bsAb immunological therapy of on-target cytotoxicity to healthy cells and a remarkable antigen-sink. Finally, we described possible mechanisms of resistance to CD47-targeted bsAb therapy. More clinical researches are supposed to adequately confirm its security and efficacy in clinical practice.

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords